Malte from Luxembourg

Registered at the short selling broker Skilling, 5 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Takeda Pharmaceutical Co., Ltd (TAK) shares information

Takeda Pharmaceutical Co., Ltd.


24h Change

1.76 %

TAK

Live rate: Market closed

Stock data per Monday 3 Aug, 2020

TAK
New York Stock Exchange
18.2
18.36
18.52
0.32 (+ 1.76%)
US Market is closed

Live Stock price in graph for Takeda Pharmaceutical Co., Ltd. (TAK)

  • Latest Volume

    815,234 (-11.09 %)

  • Volume prev. day

    916,874

  • Avg. daily volume

    1,041,591

  • Market cap

    57,700,245,280

  • P/E ratio

    1780.77

  • Today high

    18.585

  • Today low

    18.31

  • 52 week high

    20.93

  • 52 week low

    12.43

  • YTD Change

    n/a

Quick links

Broker recommendations for Takeda Pharmaceutical Co., Ltd

The Takeda Pharmaceutical Co., Ltd stock is rated at 1.192308 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 2 July, 2020 by a total of 13 brokers. This means that the consensus of the 13 different brokers is leaning toward to buy/moderate buy.

Sell
0 (0%)
Underweight
0 (0%)
Hold
2 (15.38%)
Overweight
1 (7.69%)
Buy
10 (76.92%)

Price target by analysts

The 13 latest analyst estimates, per Monday 3 August, 2020, show the following high, low and average price targets.
Target Average: 24.86 USD
Target High: 30.63 USD
Target Low: 19.32 USD

 

Latest news about Takeda Pharmaceutical Co., Ltd.

Below you can find the most recent news posts about Takeda Pharmaceutical Co., Ltd., primarily from US and UK based news sources.

AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments

Monday, 3 August 2020, 13:56:29
AbbVie Inc. undefined, Amgen Inc. undefined, and Takeda Pharmaceutical Co. Ltd. undefined announced they started enrolling patients in a clinical trial…
— MarketWatch


Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial

Monday, 3 August 2020, 13:30:00
SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ — Today, members of the COVID R&D Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to…
— PR Newswire


Global Hypoparathyroidism Pipeline Monitor 2020 with Analysis of 11 Companies Including Ascendis Pharma, Eli Lilly & Co and Takeda Pharma – ResearchAndMarkets.com

Monday, 3 August 2020, 12:50:00
DUBLIN–(BUSINESS WIRE)–The “Hypoparathyroidism Pipeline Research Monitor, 2020 – Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook” report has been added to ResearchAndMarkets.com’s offering. PIPELINE HIGHLIGHTS Hypoparathyroidism is one of the widely researched conditions during 2020 with 11 companies actively focusing on realizing pipeline’s potential. Development of Hypoparathyroidism medicines is identified as integral to the strategy of the majority of compa
— Business Wire


Takeda Pharmaceutical : Announcement of a merger (simple merger/short-form merger) with a wholly owned subsidiary | MarketScreener

Monday, 3 August 2020, 08:13:20
Osaka, Japan, August 3, 2020 — Takeda Pharmaceutical Company Limited , ‘Takeda’) decided today to perform an absorption-type merger of Shire Japan KK, which is Takeda’s… | August 3, 2020
— MarketScreener


Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full Year

Friday, 31 July 2020, 09:55:00
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2020 (quarter ended June 30, 2020). Based on the first quarter performance, the company confirms management guidance, and raises reported operating profit and reported net profit for the full year. The company also announced recent updates to its R&D pipeline and highlighted its R&D momentum with seven potential New
— Business Wire